DOCSLIB.ORG

Download CMI (PDF)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download CMI (PDF) Valganciclovir Sandoz valganciclovir hydrochloride tablet Consumer Medicine Information WHAT IS IN THIS LEAFLET neutrophils (a type of white blood cell Taking other medicines which defends against infection) or low Tell your doctor or pharmacist if you are This leaflet answers some common questions haemoglobin (oxygen carrying substance about Valganciclovir Sandoz. taking any other medicines, including any in the blood). that you get without a prescription from It does not contain all the available Some of the symptoms of an allergic reaction your pharmacy, supermarket or health information. It does not take the place of may include: food shop. talking to your doctor or pharmacist. • shortness of breath Valganciclovir Sandoz may interfere with All medicines have risks and benefits. Your • wheezing or difficulty breathing other medicines. doctor has weighed the risks of you taking this medicine against the benefits they expect • swelling of the face, lips, tongue or other These include: it will have for you. parts of the body • medicines used to treat gout such as If you have any concerns about taking this • rash, itching or hives on the skin probenecid medicine, ask your doctor or pharmacist. Do not take this medicine after the expiry • medicines used to treat HIV infection, Keep this leaflet with the medicine. date printed on the pack or if the such as zidovudine (AZT) and packaging is torn or shows signs of didanosine(ddI) WHAT IS USED FOR tampering. • a combination of medicines used to treat If it has expired or is damaged, return it to some infections, such as This medicine is used to treat: your pharmacist for disposal. imipenem/cilastatin • CMV retinitis in patients with acquired If you are not sure whether you should • medicine used to prevent organ rejection immunodeficiency syndrome (AIDS) start taking this medicine, talk to your after a transplant such as mycophenolate • Prophylaxis of CMV infection and doctor. mofetil, ciclosporin, disease following solid organ Use in children • medicines for the treatment of cancer transplantation in patients at risk of There is limited information on the safety such as vincristine, adriamycin and CMV disease. and effectiveness of the use of hydroxyurea It contains the active ingredient Valganciclovir in children. Your doctor will • anti-infective medications such as valganciclovir hydrochloride. advise you whether Valganciclovir is suitable dapsone, pentamidine, flucytosine and Valganciclovir belongs to a group of for your child. amphotericin B medicines used to prevent the growth of Before you start to take it • other medications for the treatment of viruses. Tell your doctor if you have allergies to HIV or HIV related infections such as It works by acting against a virus called any other medicines, foods, preservatives nucleoside analogues cytomegalovirus or CMV (a type of herpes or dyes. Especially any medicine which • (lamivudine, also known as 3TC; virus). It prevents this virus from growing you have taken previously to treat your stavudine, also known as D4T; and multiplying in the body. In people with current condition. zalcitabine also known as ddc; abacavir; poor immunity, CMV can cause infections. lamivudine / zidovudine or; abacavir / Poor immunity can be caused by: HIV/AIDS Tell your doctor if you have or have had lamivudine /zidovudine combinations). or by medicines taken after an organ any of the following medical conditions: transplant. • history of low blood counts for platelets These medicines may be affected by Valganciclovir Sandoz or may affect how Valganciclovir is also used to: (thrombocytopenia), neutrophils (neutropenia) or anaemia well it works. You may need different • CMV eye infections in AIDS patients, • you have or previously have had poor amounts of your medicines, or you may need which if left untreated may cause to take different medicines. blindness. It is not a cure for CMV eye kidney function Your doctor and pharmacist will have more infections Tell your doctor if you are pregnant or plan to become pregnant or are breastfeeding. information on medicines to be careful with • Prevent CMV infection in patients or avoid while taking this medicine. following organ transplantation. Valganciclovir Sandoz is not recommended for use during pregnancy. It may affect your Valganciclovir Sandoz is not effective developing baby if you take it during HOW TO TAKE VALGANCICLOVIR against any underlying HIV infection pregnancy. Your doctor can discuss with you SANDOZ Ask your doctor if you have any questions the risks and benefits involved. Follow all directions given to you by your about why this medicine has been Tell your doctor if you are breast feeding or doctor or pharmacist carefully. prescribed for you. intend to breast feed. It is not known whether They may differ from the information Your doctor may have prescribed it for Valganciclovir Sandoz passes into breast contained in this leaflet. another reason. milk. Breast feeding is not recommended If you do not understand the instructions, This medicine is available only with a during treatment with Valganciclovir ask your doctor or pharmacist for help. doctor's prescription. Sandoz. How much to take You are a woman who could become BEFORE YOU TAKE pregnant and you are not using Valganciclovir Sandoz needs to be taken VALGANCICLOVIR SANDOZ contraception. exactly as prescribed. Animal and other laboratory studies have You must use a reliable form of Your doctor will tell you how many shown Valganciclovir causes infertility, birth contraception during Valganciclovir therapy, Valganciclovir Sandoz tablets to take each defects and cancer. It is possible that these and for at least 30 days after stopping day. effects may also occur in humans. Valganciclovir, unless you are not sexually For Treatment of CMV Retinitis in AIDS When you must not take it active. You are a sexually active man. • Induction Treatment (for active CMV retinitis) Do not take this medicine if you have an You should use condoms during and for at The usual dose is 900mg (two 450mg allergy to: least 90 days following treatment with Valganciclovir unless it is certain that your tablets) twice daily with food for 21 days • valganciclovir hydrochloride , the active female partner is not at risk of pregnancy. • Maintenance Treatment (after ingredient(s), or to any of the other induction treatment or for inactive ingredient(s) listed at the end of this Information is limited on the safety and CMV retinitis) leaflet under Product Description effective of Valganciclovir Sandoz in children. Your doctor will advise. The usual dose is 900mg (two 450mg • Ganciclovir, valaciclovir or aciclovir or tablets) once daily with food. any other similar medicines If you have not told your doctor about any of the above, tell him/her before you start Prevention of CMV Disease in • If you have very low blood counts for taking Valganciclovir Sandoz. Transplantation platelets (which help clotting), Valganciclovir Sandoz Published by MIMS March 2019 1 The usual dose is 900mg (two 450mg tablets) pharmacist that you are taking Valganciclovir helps most people with CMV once daily with food, starting within 10 days VALGANCICLOVIR SANDOZ. infections but it may have unwanted side of your organ transplant until 100 days after A barrier contraceptive should be used effects in a few people. the transplant. while taking VALGANCICLOVIR All medicines can have side effects. If you have received a kidney transplant, the SANDOZ and for 90 days after stopping Sometimes they are serious, most of the time same daily dose is required until 200 days treatment. Tell your doctor if you become they are not. You may need medical attention after the transplant. Your dose may have to pregnant while taking if you get some of the side effects. be reduced or stopped if you have or develop VALGANCICLOVIR SANDOZ. Do not be alarmed by the following lists of low blood counts, have kidney disease or if Condoms should be used by sexually active side effects. You may not experience any you are older than 65 years. men while taking Valganciclovir and for 90 of them. Ask your doctor or pharmacist if you are days after stopping treatment. Ask your doctor or pharmacist to answer unsure of the correct dose for you. Women who are of childbearing potential any questions you may have. They will tell you exactly how much to take. should use contraception during and for at Tell your doctor or pharmacist if you Follow the instructions they give you. least 30 days after stopping Valganciclovir. notice any of the following and they worry If you take the wrong dose, Valganciclovir Tell any other doctors, dentists and you: Sandoz may not work as well and your pharmacists who treat you that you are • Dizziness problem may not improve. taking this medicine. • Looking pale How to take it If you are going to have surgery, tell the • Diarrhoea Swallow the tablets whole with a full glass of surgeon or anaesthetist that you are • Nausea water. Tablets must be taken with food. taking this medicine. It may affect other medicines used during • Fever When to take Valganciclovir Sandoz surgery. • Vomiting Take your medicine at about the same If you become pregnant while taking this • Headache time each day. Take during or medicine, tell your doctor immediately. immediately after a meal. If you take it on These are mild side effects of the medicine If you are about to have any blood tests, an empty stomach, it may not work as and are short-lived. tell your doctor that you are taking this well. Tell your doctor as soon as possible if you medicine. Taking it at the same time each day will have notice any of the following: It may interfere with the results of some the best effect. It will also help you tests. • skin rash remember when to take it. Your doctor may do some tests (blood cell • abdominal pain How long to take Valganciclovir counts) from time to time to make sure the • cough Sandoz medicine is working and to prevent • fatigue (tiredness) Continue taking your medicine for as long unwanted side effects.
Load more

Recommended publications
  • COVID-19) Pandemic on National Antimicrobial Consumption in Jordan
    antibiotics Article An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan Sayer Al-Azzam 1, Nizar Mahmoud Mhaidat 1, Hayaa A. Banat 2, Mohammad Alfaour 2, Dana Samih Ahmad 2, Arno Muller 3, Adi Al-Nuseirat 4 , Elizabeth A. Lattyak 5, Barbara R. Conway 6,7 and Mamoon A. Aldeyab 6,* 1 Clinical Pharmacy Department, Jordan University of Science and Technology, Irbid 22110, Jordan; [email protected] (S.A.-A.); [email protected] (N.M.M.) 2 Jordan Food and Drug Administration (JFDA), Amman 11181, Jordan; [email protected] (H.A.B.); [email protected] (M.A.); [email protected] (D.S.A.) 3 Antimicrobial Resistance Division, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland; [email protected] 4 World Health Organization Regional Office for the Eastern Mediterranean, Cairo 11371, Egypt; [email protected] 5 Scientific Computing Associates Corp., River Forest, IL 60305, USA; [email protected] 6 Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield HD1 3DH, UK; [email protected] 7 Institute of Skin Integrity and Infection Prevention, University of Huddersfield, Huddersfield HD1 3DH, UK * Correspondence: [email protected] Citation: Al-Azzam, S.; Mhaidat, N.M.; Banat, H.A.; Alfaour, M.; Abstract: Coronavirus disease 2019 (COVID-19) has overlapping clinical characteristics with bacterial Ahmad, D.S.; Muller, A.; Al-Nuseirat, respiratory tract infection, leading to the prescription of potentially unnecessary antibiotics. This A.; Lattyak, E.A.; Conway, B.R.; study aimed at measuring changes and patterns of national antimicrobial use for one year preceding Aldeyab, M.A.
    [Show full text]
  • Novel Therapeutics for Epstein–Barr Virus
    molecules Review Novel Therapeutics for Epstein–Barr Virus Graciela Andrei *, Erika Trompet and Robert Snoeck Laboratory of Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium; [email protected] (E.T.); [email protected] (R.S.) * Correspondence: [email protected]; Tel.: +32-16-321-915 Academic Editor: Stefano Aquaro Received: 15 February 2019; Accepted: 4 March 2019; Published: 12 March 2019 Abstract: Epstein–Barr virus (EBV) is a human γ-herpesvirus that infects up to 95% of the adult population. Primary EBV infection usually occurs during childhood and is generally asymptomatic, though the virus can cause infectious mononucleosis in 35–50% of the cases when infection occurs later in life. EBV infects mainly B-cells and epithelial cells, establishing latency in resting memory B-cells and possibly also in epithelial cells. EBV is recognized as an oncogenic virus but in immunocompetent hosts, EBV reactivation is controlled by the immune response preventing transformation in vivo. Under immunosuppression, regardless of the cause, the immune system can lose control of EBV replication, which may result in the appearance of neoplasms. The primary malignancies related to EBV are B-cell lymphomas and nasopharyngeal carcinoma, which reflects the primary cell targets of viral infection in vivo. Although a number of antivirals were proven to inhibit EBV replication in vitro, they had limited success in the clinic and to date no antiviral drug has been approved for the treatment of EBV infections. We review here the antiviral drugs that have been evaluated in the clinic to treat EBV infections and discuss novel molecules with anti-EBV activity under investigation as well as new strategies to treat EBV-related diseases.
    [Show full text]
  • AUSTRALIAN PRODUCT INFORMATION Valcyte® (Valganciclovir Hydrochloride)
    AUSTRALIAN PRODUCT INFORMATION Valcyte® (valganciclovir hydrochloride) 1. NAME OF THE MEDICINE Valganciclovir (as hydrochloride) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Valcyte is available as film-coated tablets and as powder for oral solution. Each film coated tablet contains 496.3 mg valganciclovir HCl (corresponding to 450 mg valganciclovir). The powder is reconstituted to form an oral solution, containing 55 mg valganciclovir HCl per mL (equivalent to 50 mg valganciclovir). Excipients with known effect The powder for oral solution contains a total of 0.188 mg/mL sodium. For the full list of excipients, see section 6.1. List of excipients 3. PHARMACEUTICAL FORM Valcyte tablets Valcyte (valganciclovir HCl) is available as 450 mg pink convex oval tablets with "VGC" on one side and "450" on the other side. Each film-coated tablet contains 450 mg valganciclovir. Valcyte is supplied in bottles of 60 tablets. Valcyte powder for oral solution Valcyte powder is white to slightly yellow. The reconstituted solution contains 50 mg/mL valganciclovir and appears clear, colourless to brownish-yellow in colour. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Valcyte is indicated for the treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS). Valcyte is indicated for the prophylaxis of CMV disease in adult and paediatric solid organ transplantation (SOT) patients who are at risk. 4.2 DOSE AND METHOD OF ADMINISTRATION Dose Caution – Strict adherence to dosage recommendations is essential to avoid overdose. Valganciclovir is rapidly and extensively converted to the active ingredient ganciclovir. The bioavailability of ganciclovir from Valcyte is up to 10-fold higher than from oral ganciclovir, ropvaley11020 1 therefore the dosage and administration of Valcyte tablets or powder for oral solution as described below should be closely followed (see sections 4.4 Special warnings and precautions for use and 4.9 Overdose).
    [Show full text]
  • Valganciclovir: Dosing Strategies for Effective Cytomegalovirus Prevention
    Trends in Transplantation 2007;1:35-43 Mark D. Pescovitz: Valganciclovir Dosing Strategies Valganciclovir: Dosing Strategies for Effective Cytomegalovirus Prevention Mark D. Pescovitz Department of Surgery and Department of Microbiology/Immunology Indiana University, Indianapolis, IN, USA Abstract Valganciclovir has widely become the agent of choice for the prevention of cytomegalovi- rus in recipients of organ transplants. Optimal dosing is needed to achieve efficacy and avoid toxicity. For subjects at high risk of cytomegalovirus, it is strongly suggested that full-dose (based on renal function) valganciclovir be used. While low-dose valganciclovir appears to be efficacious in some reports, the recommendations are based on inadequate- ly designed trials and must be taken with caution. Unfortunately, because of the sample size needed, it is not likely that the efficacy of reduced-dose valganciclovir will be ade- quately tested in well-controlled trials. The duration of prophylaxis, particularly whether prophylaxis should be extended beyond three months, continues to be an important ques- tion and is the subject of a well-designed clinical trial of which we anxiously await the results. (Trends in Transplant 2007;1:35-43) Corresponding author: Mark D. Pescovitz, [email protected] Key words Valganciclovir. Ganciclovir. Transplant. Cytomegalovirus. Children. Pharmacokinetics. Correspondence to: Mark D. Pescovitz Indiana University Medical Center Department of Surgery UH 4601 550 N University Blvd Indianapolis, IN 46202, USA Mark D. Pescovitz is a consultant to Roche and received honoraria E-mail: [email protected] for speaking and also research grants. 35 Trends in Transplantation 2007;1 ported in 1995, CMV disease developed in only ntroduction I one of 124 patients (0.8%) treated with intra- Cytomegalovirus (CMV) is the cause of venous ganciclovir (6 mg/kg/d IV for 30 days substantial morbidity in solid-organ transplant after transplantation followed by 6 mg/kg/d recipients1,2.
    [Show full text]
  • Women's Interagency Hiv Study Drug Form 2 – Non
    WOMEN’S INTERAGENCY HIV STUDY DRUG FORM 2 – NON-ANTIRETROVIRAL MEDICATION USE COMPLETE THIS FORM FOR EACH MEDICATION LISTED ON FORM F22MED, QUESTIONS C1a, C1b AND C1c. PARTICIPANT ID: |___|-|___|___|-|___|___|___|___|-|___| WIHS STUDY VISIT #: |___|___| FORM VERSION: 1 0 / 0 1 / 0 4 FORM COMPLETED BY: |___|___|___| DATE COMPLETED: |___|___| / |___|___| / |___|___| SELECT THE SPECIFIC DRUG FOR WHICH INFORMATION WILL BE CAPTURED ON THIS FORM. Inhaled Medications: 114 __ Pentamidine (aerosolized) Injected or Infused Medications: 091 __ Foscarnet (Foscavir) 157 __ Medication to increase white blood cell count 125 __ Ganciclovir (DHPG, Cytovene IV) (G-CSF, GM-CSF, Neupogen) 232 __ Nandrolone (Deca-Durabolin) 117 __ Medication to increase red blood cell count 090 __ Interferon alfa-2b (Intron A) or Interferon (Erythropoietin, Epogen, Procrit, EPO) alfa-2a (Roferon-A) 242 __ Pegylated interferon (PEGASYS, PEG-Intron, 124 __ Amphotericin B (Ampho B) Peginterferon alfa-2a, Peginterferon alfa-2b) Pills, Liquids or Creams: 112 __ Bactrim (Septra, cotrimoxazole, trimethoprim- 127 __ Nizoral (ketoconazole) sulfamethoxazole, TMP/SMZ) 144 __ Nystatin (mycostatin) 184 __ Biaxin (clarithromycin) 706 __ Orapred 153 __ Cipro (ciprofloxacin) 228 __ Oxandrin (oxandrolone) 113 __ Dapsone 707 __ Prednisolone (Prelone) 116 __ Diflucan (fluconazole) 704 __ Prednisone (Deltasone) 213 __ Famvir (famciclovir) 182 __ PZA (pyrazinamide) 125 __ Ganciclovir (Cytovene, valganciclovir, 235 __ Rebetron (ribavirin & interferon alfa-2b) Valcyte) 093 __ Rifabutin (mycobutin) 138 __ INH (isoniazid) 139 __ Rifadin (rifampin) 154 __ Lamprene (clofazimine) 169 __ Sporanox (itraconazole) 190 __ Mepron (atovaquone) 230 __ Terazol (terconazole) 540 __ Methadone 198 __ Valtrex (valacyclovir) 705 __ Methyl-prednisolone (Medrol) 247 __ Vfend (voriconazole) 229 __ Monistat (miconazole) 152 __ Zithromax (azithromycin) 137 __ Myambutol (ethambutol) 146 __ Zovirax (acyclovir) 145 __ Mycelex or Lotrimin (clotrimazole) PROMPT: INTERVIEWER, PLEASE RECORD HOW USE OF THIS MEDICATION WAS REPORTED.
    [Show full text]
  • VALGANCICLOVIR MYLAN 1. Product Name 2. Qualitative And
    NEW ZEALAND DATA SHEET VALGANCICLOVIR MYLAN 1. Product Name Valganciclovir Mylan 450 mg film-coated tablet. 2. Qualitative and Quantitative Composition Each film-coated tablet contains 496.3 mg of valganciclovir hydrochloride equivalent to 450 mg of valganciclovir. For the full list of excipients, see section 6.1. 3. Pharmaceutical Form A pink film-coated, oval, biconvex, beveled edge tablet debossed with “ M” on one side of the tablet and “ V45 ” on the other side. 4. Clinical Particulars 4.1 Therapeutic indications Valganciclovir Mylan is indicated for the treatment of cytomegalovirus (CMV) retinitis in acquired immunodeficiency syndrome (AIDS) patients. Valganciclovir Mylan Is indicated for the prevention of CMV disease in solid organ transplant patients at risk. 4.2 Dose and method of administration Caution – Strict adherence to dosage recommendations is essential to avoid overdose. Standard dosage Valganciclovir Mylan is administered orally and should be taken with food (see section 5.1). Valganciclovir Mylan is rapidly and extensively converted into the active ingredient ganciclovir. The bioavailability of ganciclovir from valganciclovir is up to 10-fold higher than from oral ganciclovir. The dosage and administration of Valganciclovir Mylan tablets as described below should be closely followed (see section 4.4). Treatment of cytomegalovirus (CMV) retinitis Adult patients Induction treatment of CMV retinitis For patients with CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) with food twice a day for 21 days. Prolonged induction treatment may increase the risk of bone marrow toxicity (see section 4.4). Page 1 of 20 Maintenance treatment of CMV retinitis Following induction treatment, or in patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) with food once daily.
    [Show full text]
  • Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patien
    1 2 3 PROJECT TITLE 4 Anti-viral Prophylaxis for Prevention of Cytomegalovirus (CMV) Reactivation in Immunocompetent 5 Patients in Critical Care 6 7 STUDY ACRONYM 8 Cytomegalovirus Control in Critical Care - CCCC 9 10 APPLICANTS 11 Dr Nicholas Cowley 12 Specialty Registrar Anaesthesia and Intensive Care Medicine, Intensive Care Research Fellow 13 Queen Elizabeth Hospital Birmingham 14 15 Professor Paul Moss 16 Professor of Haematology 17 Queen Elizabeth Hospital Birmingham 18 19 Professor Julian Bion 20 Professor of Intensive Care Medicine 21 Queen Elizabeth Hospital Birmingham 22 23 Trial Virologist Trial Statistician 24 Dr H Osman Dr P G Nightingale 25 Queen Elizabeth Hospital Birmingham University of Birmingham CCCC CMV Protocol V1.7, 18th September 2013 1 Downloaded From: https://jamanetwork.com/ on 09/23/2021 26 CONTENTS 27 Substantial Amendment Sept 18th 2013 4 28 1 SUMMARY OF TRIAL DESIGN .......................................................................................................... 5 29 2 QEHB ICU Duration of Patient Stay ................................................................................................. 6 30 3 SCHEMA - QEHB PATIENT NUMBERS AVAILABLE FOR RECRUITMENT ........................................... 6 31 4 INTRODUCTION ............................................................................................................................... 7 32 4.1 CMV latent infection is widespread ........................................................................................ 7 33 4.2 CMV Reactivation
    [Show full text]
  • Valganciclovir (Valcyte) Reference Number: CP.PCH.06 Effective Date: 12.01.17 Last Review Date: 02.20 Line of Business: Commercial, HIM* Revision Log
    Clinical Policy: Valganciclovir (Valcyte) Reference Number: CP.PCH.06 Effective Date: 12.01.17 Last Review Date: 02.20 Line of Business: Commercial, HIM* Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Valganciclovir (Valcyte®) is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor. ____________ *For Health Insurance Marketplace (HIM), valganciclovir oral solution 50 mg/mL is non-formulary and cannot be approved using these criteria; refer to the formulary exception policy, HIM.PA.103. FDA Approved Indication(s) Valcyte is indicated for: • Adult patients • Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). • For the prevention of CMV disease in kidney, heart, or kidney-pancreas transplant patients at high risk (donor CMV seropositive/recipient CMV seronegative [D+/R-]). • Pediatric patients • Prevention of CMV disease in kidney (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Valcyte is medically necessary when the following criteria are met: I. Initial Approval Criteria A. CMV Prophylaxis in Heart, Kidney, or Kidney-Pancreas Transplant (must meet all): 1. Member has a history of heart, kidney, or kidney-pancreas transplant; 2. Organ donor or recipient is CMV seropositive; 3. Dose does not exceed 900 mg per day. Approval duration: Heart or kidney-pancreas transplant: 6 months Kidney transplant: 200 days (For HIM, approve valganciclovir tablets 450 mg only.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Iga Vasculitis Complicated by Both CMV Reactivation and Tuberculosis
    Case Report IgA Vasculitis Complicated by Both CMV Reactivation and Tuberculosis Małgorzata Mizerska-Wasiak 1,*, Maria Winiarska 2, Karolina Nogal 2, Karolina Cicho ´n-Kawa 1, Małgorzata Pa ´nczyk-Tomaszewska 1 and Jadwiga Małdyk 3 1 Department of Pediatrics and Nephrology, Medical University of Warsaw, 02-091 Warsaw, Poland; [email protected] (K.C.-K.); [email protected] (M.P.-T.) 2 Student’s Scientific Group at the Department of Pediatrics and Nephrology, Medical University of Warsaw, 02-091 Warsaw, Poland; [email protected] (M.W.); [email protected] (K.N.) 3 Department of Pathology, Medical University of Warsaw, 02-091 Warsaw, Poland; [email protected] * Correspondence: [email protected] Abstract: Immunoglobulin A (IgA) vasculitis is the most common systemic vasculitis in the pediatric population. We present the case of a patient with IgA vasculitis with nephritis who developed cy- tomegalovirus (CMV) infection followed by Mycobacterium tuberculosis infection. In the literature, there are a few cases of IgA nephropathy accompanied by reactivation of CMV or tuberculosis. To the best of our knowledge, this is the first reported case of IgA vasculitis complicated by both CMV reactivation and tuberculosis. It is important to detect infections in patients with IgA vasculitis be- cause they can induce and exacerbate the symptoms of the disease. Effective antimicrobial treatment facilitates the management of proteinuria and slows down the decline of renal function. Immuno- suppressive therapy is a risk factor for reactivation of latent infections and makes patients more Citation: Mizerska-Wasiak, M.; Winiarska, M.; Nogal, K.; susceptible to its generalized and complicated course.
    [Show full text]
  • World Health Organization Model List of Essential Medicines, 21St List, 2019
    World Health Organizatio n Model List of Essential Medicines 21st List 2019 World Health Organizatio n Model List of Essential Medicines 21st List 2019 WHO/MVP/EMP/IAU/2019.06 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
    [Show full text]
  • Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2
    viruses Review Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2 Lauren A. Sadowski 1,†, Rista Upadhyay 1,2,†, Zachary W. Greeley 1,‡ and Barry J. Margulies 1,3,* 1 Towson University Herpes Virus Lab, Department of Biological Sciences, Towson University, Towson, MD 21252, USA; [email protected] (L.A.S.); [email protected] (R.U.); [email protected] (Z.W.G.) 2 Towson University Department of Chemistry, Towson, MD 21252, USA 3 Molecular Biology, Biochemistry, and Bioinformatics Program, Towson University, Towson, MD 21252, USA * Correspondence: [email protected] † Authors contributed equally to this manuscript. ‡ Current address: Becton-Dickinson, Sparks, MD 21152, USA. Abstract: Herpes simplex viruses-1 and -2 (HSV-1 and -2) are two of the three human alphaher- pesviruses that cause infections worldwide. Since both viruses can be acquired in the absence of visible signs and symptoms, yet still result in lifelong infection, it is imperative that we provide interventions to keep them at bay, especially in immunocompromised patients. While numerous experimental vaccines are under consideration, current intervention consists solely of antiviral chemotherapeutic agents. This review explores all of the clinically approved drugs used to prevent the worst sequelae of recurrent outbreaks by these viruses. Keywords: acyclovir; ganciclovir; cidofovir; vidarabine; foscarnet; amenamevir; docosanol; nelfi- navir; HSV-1; HSV-2 Citation: Sadowski, L.A.; Upadhyay, R.; Greeley, Z.W.; Margulies, B.J. Current Drugs to Treat Infections 1. Introduction with Herpes Simplex Viruses-1 and -2. The world of anti-herpes simplex (anti-HSV) agents took flight in 1962 with the FDA Viruses 2021, 13, 1228.
    [Show full text]